{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:32:20Z","timestamp":1792891940584,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis\u00a0(NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report that prophylactic but not therapeutic administration of obeticholic acid (OCA) prevents hepatic stellate cell (HSC) activation and fibrogenesis. Activated HSCs show limited response to OCA and other FXR agonists due to enhanced FXR SUMOylation. SUMOylation inhibitors rescue FXR signaling and thereby increasing the efficacy of OCA against HSC activation and fibrosis. FXR upregulates <jats:italic>Perilipin-1<\/jats:italic>, a direct target gene of FXR, to stabilize lipid droplets and thereby prevent HSC activation. Therapeutic coadministration of OCA and SUMOylation inhibitors drastically impedes liver fibrosis induced by CCl<jats:sub>4<\/jats:sub>, bile duct ligation, and more importantly NASH. In conclusion, we propose a promising therapeutic approach by combining SUMOylation inhibitors and FXR agonists for liver fibrosis.<\/jats:p>","DOI":"10.1038\/s41467-019-14138-6","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T11:02:41Z","timestamp":1578913361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-3099","authenticated-orcid":false,"given":"Jiyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-3141","authenticated-orcid":false,"given":"Shuang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-7957","authenticated-orcid":false,"given":"Qingxian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6753-6040","authenticated-orcid":false,"given":"Xiaojie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1364-6754","authenticated-orcid":false,"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-9857","authenticated-orcid":false,"given":"Ningning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0082-1146","authenticated-orcid":false,"given":"Chaoliang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-1921","authenticated-orcid":false,"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-2140","authenticated-orcid":false,"given":"Frank J.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-3082","authenticated-orcid":false,"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2522-7546","authenticated-orcid":false,"given":"Haiping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"14138_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10713","volume":"7","author":"N Gomez-Ospina","year":"2016","unstructured":"Gomez-Ospina, N. et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat. Commun. 7, 10713 (2016).","journal-title":"Nat. Commun."},{"key":"14138_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","volume":"102","author":"CJ Sinal","year":"2000","unstructured":"Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell 102, 731\u2013744 (2000).","journal-title":"Cell"},{"key":"14138_CR3","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362\u20131365 (1999).","journal-title":"Science"},{"key":"14138_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","volume":"3","author":"H Wang","year":"1999","unstructured":"Wang, H., Chen, J., Hollister, K., Sowers, L. C. & Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR. Mol. Cell 3, 543\u2013553 (1999).","journal-title":"Mol. Cell"},{"key":"14138_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365\u20131368 (1999).","journal-title":"Science"},{"key":"14138_CR6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","volume":"25","author":"H Hao","year":"2017","unstructured":"Hao, H. et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis. Cell Metab. 25, 856\u2013867 (2017).","journal-title":"Cell Metab."},{"key":"14138_CR7","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"YD Wang","year":"2008","unstructured":"Wang, Y. D. et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48, 1632\u20131643 (2008).","journal-title":"Hepatology"},{"key":"14138_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","volume":"176","author":"T Fu","year":"2019","unstructured":"Fu, T. et al. FXR regulates intestinal cancer stem cell proliferation. Cell 176, 1098\u20131112 (2019).","journal-title":"Cell"},{"key":"14138_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature13949","volume":"516","author":"S Seok","year":"2014","unstructured":"Seok, S. et al. Transcriptional regulation of autophagy by an FXR-CREB axis. Nature 516, 108\u2013111 (2014).","journal-title":"Nature"},{"key":"14138_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature13961","volume":"516","author":"JM Lee","year":"2014","unstructured":"Lee, J. M. et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516, 112\u2013115 (2014).","journal-title":"Nature"},{"key":"14138_CR11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.28836","volume":"64","author":"CD Fuchs","year":"2016","unstructured":"Fuchs, C. D., Schwabl, P., Reiberger, T. & Trauner, M. Liver capsule: FXR agonists against liver disease. Hepatology 64, 1773 (2016).","journal-title":"Hepatology"},{"key":"14138_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.30513","volume":"70","author":"JM Ferrell","year":"2019","unstructured":"Ferrell, J. M., Pathak, P., Boehme, S., Gilliland, T. & Chiang, J. Y. L. Deficiency of both Farnesoid X receptor and Takeda G protein-coupled receptor 5 exacerbated liver fibrosis in mice. Hepatology 70, 955\u2013970 (2019).","journal-title":"Hepatology"},{"key":"14138_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/13543776.2018.1527906","volume":"28","author":"H Wang","year":"2018","unstructured":"Wang, H., He, Q., Wang, G., Xu, X. & Hao, H. FXR modulators for enterohepatic and metabolic diseases. Expert Opin. Ther. Pat. 28, 765\u2013782 (2018).","journal-title":"Expert Opin. Ther. Pat."},{"key":"14138_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10853-2","volume":"10","author":"D Merk","year":"2019","unstructured":"Merk, D. et al. Molecular tuning of farnesoid X receptor partial agonism. Nat. Commun. 10, 2915 (2019).","journal-title":"Nat. Commun."},{"key":"14138_CR15","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1016\/j.bmcl.2017.06.003","volume":"27","author":"H Wang","year":"2017","unstructured":"Wang, H. et al. A novel intestinal-restricted FXR agonist. Bioorg. Med. Chem. Lett. 27, 3386\u20133390 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"14138_CR16","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari, R. et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569\u20133572 (2002).","journal-title":"J. Med. Chem."},{"key":"14138_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cell.2016.08.001","volume":"166","author":"CD De Magalhaes Filho","year":"2016","unstructured":"De Magalhaes Filho, C. D., Downes, M. & Evans, R. Bile acid analog itercepts liver fibrosis. Cell 166, 789 (2016).","journal-title":"Cell"},{"key":"14138_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/hep.28932","volume":"65","author":"S Samur","year":"2017","unstructured":"Samur, S. et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology 65, 920\u2013928 (2017).","journal-title":"Hepatology"},{"key":"14138_CR19","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196 (2019).","journal-title":"Lancet"},{"key":"14138_CR20","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(19)32963-0","volume":"394","author":"M Eslam","year":"2019","unstructured":"Eslam, M., Alvani, R. & Shiha, G. Obeticholic acid: towards first approval for NASH. Lancet 394, 2131\u20133133 (2019).","journal-title":"Lancet"},{"key":"14138_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631\u2013643 (2016).","journal-title":"N. Engl. J. Med."},{"key":"14138_CR22","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","volume":"67","author":"KV Kowdley","year":"2018","unstructured":"Kowdley, K. V. et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 67, 1890\u20131902 (2018).","journal-title":"Hepatology"},{"key":"14138_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ebiom.2018.10.028","volume":"37","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis. EBioMedicine 37, 322\u2013333 (2018).","journal-title":"EBioMedicine"},{"key":"14138_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","volume":"15","author":"RF Schwabe","year":"2018","unstructured":"Schwabe, R. F. & Luedde, T. Apoptosis and necroptosis in the liver: a matter of life and death. Nat. Rev. Gastroenterol. Hepatol. 15, 738\u2013752 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"14138_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04450-y","volume":"9","author":"P Hegde","year":"2018","unstructured":"Hegde, P. et al. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nat. Commun. 9, 2146 (2018).","journal-title":"Nat. Commun."},{"key":"14138_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41575-018-0045-2","volume":"15","author":"M Bernardi","year":"2018","unstructured":"Bernardi, M. & Caraceni, P. Novel perspectives in the management of decompensated cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 15, 753\u2013764 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"14138_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama, Y. & Brenner, D. A. Liver inflammation and fibrosis. J. Clin. Invest. 127, 55\u201364 (2017).","journal-title":"J. Clin. Invest."},{"key":"14138_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397\u2013411 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"14138_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jhep.2013.11.007","volume":"60","author":"LM Pawella","year":"2014","unstructured":"Pawella, L. M. et al. Perilipin discerns chronic from acute hepatocellular steatosis. J. Hepatol. 60, 633\u2013642 (2014).","journal-title":"J. Hepatol."},{"key":"14138_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.tcb.2016.02.007","volume":"26","author":"N Kory","year":"2016","unstructured":"Kory, N., Farese, R. V. Jr. & Walther, T. C. Targeting fat: mechanisms of protein localization to lipid droplets. Trends Cell Biol. 26, 535\u2013546 (2016).","journal-title":"Trends Cell Biol."},{"key":"14138_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03717-8","volume":"9","author":"A Copic","year":"2018","unstructured":"Copic, A. et al. A giant amphipathic helix from a perilipin that is adapted for coating lipid droplets. Nat. Commun. 9, 1332 (2018).","journal-title":"Nat. Commun."},{"key":"14138_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08411-x","volume":"10","author":"K Soltysik","year":"2019","unstructured":"Soltysik, K., Ohsaki, Y., Tatematsu, T., Cheng, J. & Fujimoto, T. Nuclear lipid droplets derive from a lipoprotein precursor and regulate phosphatidylcholine synthesis. Nat. Commun. 10, 473 (2019).","journal-title":"Nat. Commun."},{"key":"14138_CR33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1124\/jpet.105.084905","volume":"314","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci, S. et al. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 314, 584\u2013595 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"14138_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1124\/mol.110.068247","volume":"80","author":"J Li","year":"2011","unstructured":"Li, J. et al. Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol. Pharmacol. 80, 191\u2013200 (2011).","journal-title":"Mol. Pharmacol."},{"key":"14138_CR35","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/hep.26939","volume":"59","author":"L Verbeke","year":"2014","unstructured":"Verbeke, L. et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286\u20132298 (2014).","journal-title":"Hepatology"},{"key":"14138_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1124\/jpet.105.085597","volume":"315","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci, S. et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J. Pharmacol. Exp. Ther. 315, 58\u201368 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"14138_CR37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497\u20131512 (2004).","journal-title":"Gastroenterology"},{"key":"14138_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep33453","volume":"6","author":"L Verbeke","year":"2016","unstructured":"Verbeke, L. et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci. Rep. 6, 33453 (2016).","journal-title":"Sci. Rep."},{"key":"14138_CR39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","volume":"9","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis. Acta Pharm. Sin. B 9, 526\u2013536 (2019).","journal-title":"Acta Pharm. Sin. B"},{"key":"14138_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04697-5","volume":"9","author":"S Byun","year":"2018","unstructured":"Byun, S. et al. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. Nat. Commun. 9, 2590 (2018).","journal-title":"Nat. Commun."},{"key":"14138_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08730-z","volume":"10","author":"FP Zhang","year":"2019","unstructured":"Zhang, F. P. et al. Lack of androgen receptor SUMOylation results in male infertility due to epididymal dysfunction. Nat. Commun. 10, 777 (2019).","journal-title":"Nat. Commun."},{"key":"14138_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01271-3","volume":"8","author":"RJ Lumpkin","year":"2017","unstructured":"Lumpkin, R. J. et al. Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat. Commun. 8, 1171 (2017).","journal-title":"Nat. Commun."},{"key":"14138_CR43","doi-asserted-by":"publisher","first-page":"13850","DOI":"10.1074\/jbc.M112.443937","volume":"288","author":"N Balasubramaniyan","year":"2013","unstructured":"Balasubramaniyan, N., Luo, Y., Sun, A. Q. & Suchy, F. J. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J. Biol. Chem. 288, 13850\u201313862 (2013).","journal-title":"J. Biol. Chem."},{"key":"14138_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/jmcb\/mjx009","volume":"9","author":"S Bilodeau","year":"2017","unstructured":"Bilodeau, S., Caron, V., Gagnon, J., Kuftedjian, A. & Tremblay, A. A CK2-RNF4 interplay coordinates non-canonical SUMOylation and degradation of nuclear receptor FXR. J. Mol. Cell. Biol. 9, 195\u2013208 (2017).","journal-title":"J. Mol. Cell. Biol."},{"key":"14138_CR45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/hep.27645","volume":"62","author":"F O\u2019Mahony","year":"2015","unstructured":"O\u2019Mahony, F. et al. Liver X receptors balance lipid stores in hepatic stellate cells through Rab18, a retinoid responsive lipid droplet protein. Hepatology 62, 615\u2013626 (2015).","journal-title":"Hepatology"},{"key":"14138_CR46","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/ncb3166","volume":"17","author":"S Kaushik","year":"2015","unstructured":"Kaushik, S. & Cuervo, A. M. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nat. Cell Biol. 17, 759\u2013770 (2015).","journal-title":"Nat. Cell Biol."},{"key":"14138_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2581","volume":"4","author":"Z Sun","year":"2013","unstructured":"Sun, Z. et al. Perilipin1 promotes unilocular lipid droplet formation through the activation of Fsp27 in adipocytes. Nat. Commun. 4, 1594 (2013).","journal-title":"Nat. Commun."},{"key":"14138_CR48","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/cr.2008.289","volume":"18","author":"YD Wang","year":"2008","unstructured":"Wang, Y. D., Chen, W. D., Moore, D. D. & Huang, W. FXR: a metabolic regulator and cell protector. Cell Res. 18, 1087\u20131095 (2008).","journal-title":"Cell Res."},{"key":"14138_CR49","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","volume":"51","author":"S Zhang","year":"2009","unstructured":"Zhang, S., Wang, J., Liu, Q. & Harnish, D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51, 380\u2013388 (2009).","journal-title":"J. Hepatol."},{"key":"14138_CR50","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","volume":"66","author":"P Schwabl","year":"2017","unstructured":"Schwabl, P. et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J. Hepatol. 66, 724\u2013733 (2017).","journal-title":"J. Hepatol."},{"key":"14138_CR51","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574\u2013582 (2013).","journal-title":"Gastroenterology"},{"key":"14138_CR52","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965 (2015).","journal-title":"Lancet"},{"key":"14138_CR53","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","volume":"62","author":"C Trautwein","year":"2015","unstructured":"Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fibrosis: concept to treatment. J. Hepatol. 62, S15\u2013S24 (2015).","journal-title":"J. Hepatol."},{"key":"14138_CR54","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrgastro.2015.224","volume":"13","author":"K Poelstra","year":"2016","unstructured":"Poelstra, K. Liver fibrosis in 2015: Crucial steps towards an effective treatment. Nat. Rev. Gastroenterol. Hepatol. 13, 67\u201368 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"14138_CR55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.15252\/embj.201489527","volume":"34","author":"DH Kim","year":"2015","unstructured":"Kim, D. H. et al. A dysregulated acetyl\/SUMO switch of FXR promotes hepatic inflammation in obesity. EMBO J. 34, 184\u2013199 (2015).","journal-title":"EMBO J."},{"key":"14138_CR56","doi-asserted-by":"publisher","first-page":"288ra275","DOI":"10.1126\/scitranslmed.3010572","volume":"7","author":"DF Bruhn","year":"2015","unstructured":"Bruhn, D. F. et al. Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections. Sci. Transl. Med. 7, 288ra275 (2015).","journal-title":"Sci. Transl. Med."},{"key":"14138_CR57","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/j.1552-4604.1974.tb02326.x","volume":"14","author":"E Novak","year":"1974","unstructured":"Novak, E., Schlagel, C. A., LeZotte, L. A. & Pfeifer, R. T. The tolerance of high dose intravenous spectinomycin therapy in man. J. Clin. Pharmacol. 14, 442\u2013447 (1974).","journal-title":"J. Clin. Pharmacol."},{"key":"14138_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.chembiol.2009.01.009","volume":"16","author":"I Fukuda","year":"2009","unstructured":"Fukuda, I. et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 16, 133\u2013140 (2009).","journal-title":"Chem. Biol."},{"key":"14138_CR59","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1021\/cb400630z","volume":"8","author":"M Hirohama","year":"2013","unstructured":"Hirohama, M. et al. Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2. ACS Chem. Biol. 8, 2635\u20132642 (2013).","journal-title":"ACS Chem. Biol."},{"key":"14138_CR60","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1002\/hep.29041","volume":"65","author":"FV Bruschi","year":"2017","unstructured":"Bruschi, F. V. et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology 65, 1875\u20131890 (2017).","journal-title":"Hepatology"},{"key":"14138_CR61","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/hep.26318","volume":"57","author":"A Chen","year":"2013","unstructured":"Chen, A. et al. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology 57, 2202\u20132212 (2013).","journal-title":"Hepatology"},{"key":"14138_CR62","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.molmet.2016.02.002","volume":"5","author":"K Okada","year":"2016","unstructured":"Okada, K. et al. Thioesterase superfamily member 1 suppresses cold thermogenesis by limiting the oxidation of lipid droplet-derived fatty acids in brown adipose tissue. Mol. Metab. 5, 340\u2013351 (2016).","journal-title":"Mol. Metab."},{"key":"14138_CR63","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev-nutr-071813-105410","volume":"36","author":"AR Kimmel","year":"2016","unstructured":"Kimmel, A. R. & Sztalryd, C. The perilipins: major cytosolic lipid droplet-associated proteins and their roles in cellular lipid storage, mobilization, and systemic homeostasis. Annu. Rev. Nutr. 36, 471\u2013509 (2016).","journal-title":"Annu. Rev. Nutr."},{"key":"14138_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/srep18751","volume":"6","author":"Y Xie","year":"2016","unstructured":"Xie, Y. et al. Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming. Sci. Rep. 6, 18751 (2016).","journal-title":"Sci. Rep."},{"key":"14138_CR65","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1124\/dmd.114.061622","volume":"43","author":"H Wang","year":"2015","unstructured":"Wang, H. et al. Mechanism-based inhibitory and peroxisome proliferator-activated receptor alpha-dependent modulating effects of silybin on principal hepatic drug-metabolizing enzymes. Drug Metab. Dispos. 43, 444\u2013454 (2015).","journal-title":"Drug Metab. Dispos."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14138-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:02:52Z","timestamp":1748001772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14138-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["14138"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-14138-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, the \u201cLipid Loaded for 16 h\u201d image in Supplementary Fig. 9e was incorrect. The amended Supplementary information is now available online.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}